d'Oliveira & Associates Offers a “No Win No Fee Promise” to Those Injured from the Hair Loss Drug Propecia

Share Article

Side Effects allegedly associated with long-term Propecia use may persist even after discontinuing use of the hair-loss preventing drug.

The law firm of d’Oliveira & Associates is working with some of the leading Propecia lawyers in the country handling Propecia cases and want the public to know that they offer a “No Win No Fee Promise” for Propecia users who have allegedly developed either breast or prostate cancer or suffered a permanent sexual dysfunction as a result of propeica use.

ABC News reported that the popular hair-loss drug, Propecia, has been linked to its increases in its users developing permanent sexual dysfunctions (i). ABC News referenced a study that was published in the Journal of Sexual Medicine and conducted by researchers at George Washington University that found Propecia's use poses a significant threat to incompetence in its users. According to the same article, Propecia’s side effects may persist for months or years after discontinuing use of the drug (ii).

Marketed by Merck & Co., Inc., Propecia is a commonly used drug meant to stop hair loss in men that was approved by The U.S. Food and Drug Administration (FDA) in 1997. In the 15 years since its approval, Propecia has been the center of several international studies examining the drug's link to both sexual dysfunction and breast and prostate cancer. The FDA cited a study conducted by the Medical Therapy of Prostatic Symptoms, when it announced that it was not ready to rule out the possibility that Propecia increases a user's risk of developing breast or prostate cancer (iii). Also recently, Health Canada reached a similar conclusion when it received numerous reports of Propecia users developing male breast cancer (iv).

In addition to Propecia's links to breast and prostate cancer, the drug has now been attacked for its links of causing long-term and permanent sexual dysfunction in its users. Similar to the claims of cancer risks, Propecia's links to permanent dysfunctions have been studied in numerous countries. In 2008, the Swedish Medical Products Agency investigated the risk and urged Swedish authorities to force Merck to include in its warnings the risk or "persistent erectile dysfunction (v)." Additionally, in the George Washington University study, researchers found that Propecia users, who showed no symptoms of dysfunction prior to the study, were are a significantly increased risk, and that for those men who suffered from the side effects, that 96% of them reported it lasting for over a year after stopping Propecia use (vi).

To help protect the rights of individuals who may have suffered injuries sexual dysfunction or even breast or prostate cancer while using Propecia to treat hair loss, d'Oliveira & Associates is offering a No Win, No Fee Promise. Those who choose to hire d'Oliveira & Associates will be charged no fee unless they recover monetary damages, such as through a settlement or judgment.

If you or one of your loved ones have been injured by Propecia or Proscar, you may want to speak with a personal injury lawyer regarding a dangerous drug claim. A Propecia lawyer familiar with new developments in the litigation of the drug Propecia may be able to help you make important personal and legal decisions. d'Oliveira & Associates, P.C. is working with some of the leading Propecia lawyers and dangerous drug attorneys in the country who are handling these cases.

Please contact the law offices of d'Oliveira & Associates, P.C. at 1-800-992-6878 or fill out a contact form for a free legal consultation.

(i) abcnews.go.com/Health/baldness-drug-propecia-long-lasting-possibly-permanent-sexual/story?id=16758123#.UGnwPE2xJok
(ii) onlinelibrary.wiley.com/doi/10.1111/j.1743-6109.2011.02255.x/abstract
(iii) http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm208701.htm
(iv) cbc.ca/news/health/story/2011/08/04/finasteride-breast.html
(v) http://www.news-medical.net/health/Finasteride-Side-Effects.aspx
(vi) http://www.medicalnewstoday.com/articles/247858.php

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Paul d'Oliveira
Visit website